Summary: PathAI's AIM-MASH receives FDA qualification

Why It Matters: This is a major regulatory win. It makes the tool the first of its kind approved for use in specific clinical trials. This helps the company stand out to drug makers who need official tools for their research.

What Changed:

• Replaced a news item about Moffitt Cancer Center with a new headline about AIM-MASH FDA qualification.
• Updated the featured news section to highlight the December 09, 2025, announcement.
• Added a specific marketing tracking code (MKT-012-15) to the website footer.